Loading
A phase 1/2 trial of Loncastuximab tesirine in diffuse large b-cell lymphoma, run by Tanabe Pharma Corporation, active and no longer recruiting.
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL is a phase 1/2 interventional study registered as NCT05658562 by Tanabe Pharma Corporation, with 46 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2028-08. Interventions recorded: MT-2111. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/